KATIE WALLACE: Open Payments
NPI 1952703092 · BURLINGTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 21 payments from 10 companies in 2025. Trend: 2023 $17 · 2024 $99 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 7 | $200 |
| Amgen Inc. | 4 | $109 |
| GENZYME CORPORATION | 2 | $42 |
| Galderma Laboratories, L.P. | 2 | $34 |
| Organon LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| ABBVIE INC. | 1 | $14 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
| E.R. Squibb & Sons, L.L.C. | 1 | $13 |
Products named: Bimzelx, Otezla, DUPIXENT, NEMLUVIO, VTAMA, TALTZ, SKYRIZI, Zoryve.
Industry payments across MA — which companies pay providers there.
